The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications
Open accessAbstract
Aptamers are oligonucleotide sequences with a length of about 25-80 bases which have abilities to bind to specific target molecules that rival those of monoclonal antibodies. They are attracting great attention in diverse clinical translations on account of their various advantages, including prolonged storage life, little batch-to-batch differences, very low immunogenicity, and feasibility of chemical modifications for enhancing stability, prolonging the half-life in serum, and targeted delivery. In this Review, we demonstrate the emerging aptamer discovery technologies in developing advanced techniques for producing aptamers with high performance consistently and efficiently as well as requiring less cost and resources but offering a great chance of success. Further, the diverse modifications of aptamers for therapeutic applications including therapeutic agents, aptamer-drug conjugates, and targeted delivery materials are comprehensively summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Li, F., Lu, J., Liu, J., Liang, C., Wang, M., Wang, L., Li, D., Yao, H., Zhang, Q., Wen, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01565-6 · Cited by 281
Self-citationRetractedTuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Self-citationCell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Yeh, M.-K., Chang, H.-I., & Cheng, M.-Y. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s26766 · Cited by 801
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
The emerging field of RNA nanotechnology
Guo, P. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2010.231 · Cited by 718
Recent Advances in Aptamer Discovery and Applications
Zhang, Y., Lai, B. S., & Juhas, M. (2019) · Molecules · doi:10.3390/molecules24050941 · Cited by 663
Aptamers from Cell-Based Selection for Bioanalytical Applications
Tan, W., Donovan, M. J., & Jiang, J. (2013) · Chemical Reviews · doi:10.1021/cr300468w · Cited by 649
An Aptamer–Doxorubicin Physical Conjugate as a Novel Targeted Drug‐Delivery Platform
Bagalkot, V., Farokhzad, O. C., Langer, R., & Jon, S. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602251 · Cited by 613
Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 610
Dassie, J. P., Liu, X.-Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 589
Aptamer-based targeted therapy
Zhu, G., & Chen, X. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.005 · Cited by 522
Generation of high-affinity DNA aptamers using an expanded genetic alphabet
Kimoto, M., Yamashige, R., Matsunaga, K.-I., Yokoyama, S., & Hirao, I. (2013) · Nature Biotechnology · doi:10.1038/nbt.2556 · Cited by 510
Li, J., Zheng, C., Cansiz, S., Wu, C., Xu, J., Cui, C., Liu, Y., Hou, W., Wang, Y., Zhang, L., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/ja512293f · Cited by 499
Self-citationMolecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells
Huang, Y., Shangguan, D., Liu, H., Phillips, J. A., Zhang, X., Chen, Y., & Tan, W. (2009) · ChemBioChem · doi:10.1002/cbic.200800805 · Cited by 422
Mirror-image RNA that binds D-adenosine
Klußmann, S., Nolte, A., Bald, R., Erdmann, V. A., & Fürste, J. P. (1996) · Nature Biotechnology · doi:10.1038/nbt0996-1112 · Cited by 399
Reversible Cell‐Specific Drug Delivery with Aptamer‐Functionalized Liposomes
Cao, Z., Tong, R., Mishra, A., Xu, W., Wong, G. C. L., Cheng, J., & Lu, Y. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200901452 · Cited by 372
Engineering Target-Responsive Hydrogels Based on Aptamer−Target Interactions
Yang, H., Liu, H., Kang, H., & Tan, W. (2008) · Journal of the American Chemical Society · doi:10.1021/ja801339w · Cited by 363
Liang, C., Guo, B., Wu, H., Shao, N., Li, D., Liu, J., Dang, L., Wang, C., Li, H., Li, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3791 · Cited by 354
Self-citationMicromagnetic selection of aptamers in microfluidic channels
Lou, X., Qian, J., Xiao, Y., Viel, L., Gerdon, A. E., Lagally, E. T., Atzberger, P., Tarasow, T. M., Heeger, A. J., & Soh, H. T. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813135106 · Cited by 349
Direct In Vitro Selection of a 2′-O-Methyl Aptamer to VEGF
Burmeister, P. E., Lewis, S. D., Silva, R. F., Preiss, J. R., Horwitz, L. R., Pendergrast, P. S., McCauley, T. G., Kurz, J. C., Epstein, D. M., Wilson, C., et al. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.10.017 · Cited by 347
Yan, L., Zhu, Z., Zou, Y., Huang, Y., Liu, D., Jia, S., Xu, D., Wu, M., Zhou, Y., Zhou, S., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja3114714 · Cited by 329
Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes
Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., & Zhang, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081683 · Cited by 321
Self-citationExpanding the Chemistry of DNA for in Vitro Selection
Vaught, J. D., Bock, C., Carter, J., Fitzwater, T., Otis, M., Schneider, D., Rolando, J., Waugh, S., Wilcox, S. K., & Eaton, B. E. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908035g · Cited by 313
Liposome-based drug co-delivery systems in cancer cells
Zununi Vahed, S., Salehi, R., Davaran, S., & Sharifi, S. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.11.073 · Cited by 307
Zhu, Z., Guan, Z., Jia, S., Lei, Z., Lin, S., Zhang, H., Ma, Y., Tian, Z., & Yang, C. J. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201405995 · Cited by 303
Pharmacokinetics and Biodistribution of Novel Aptamer Compositions
Healy, J. M., Lewis, S. D., Kurz, M., Boomer, R. M., Thompson, K. M., Wilson, C., & McCauley, T. G. (2004) · Pharmaceutical Research · doi:10.1007/s11095-004-7676-4 · Cited by 298
Li, L., Hou, J., Liu, X., Guo, Y., Wu, Y., Zhang, L., & Yang, Z. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.01.019 · Cited by 289
Self-citationApplication of locked nucleic acids to improve aptamer in vivo stability and targeting function
Schmidt, K. S. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh862 · Cited by 287
Green, L. S., Jellinek, D., Bell, C., Beebe, L. A., Feistner, B. D., Gill, S. C., Jucker, F. M., & Janjić, N. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90032-2 · Cited by 284
In vivo selection of tumor-targeting RNA motifs
Mi, J., Liu, Y., Rabbani, Z. N., Yang, Z., Urban, J. H., Sullenger, B. A., & Clary, B. M. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.277 · Cited by 269
Self-citationMallikaratchy, P., Tang, Z., Kwame, S., Meng, L., Shangguan, D., & Tan, W. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700026-mcp200 · Cited by 268
Irvine, D., Tuerk, C., & Gold, L. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90509-5 · Cited by 266
Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer® therapeutics
Vater, A., & Klussmann, S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.004 · Cited by 250
Hoellenriegel, J., Zboralski, D., Maasch, C., Rosin, N. Y., Wierda, W. G., Keating, M. J., Kruschinski, A., & Burger, J. A. (2014) · Blood · doi:10.1182/blood-2013-03-493924 · Cited by 242
Evolution of Functional Six-Nucleotide DNA
Zhang, L., Yang, Z., Sefah, K., Bradley, K. M., Hoshika, S., Kim, M.-J., Kim, H.-J., Zhu, G., Jiménez, E., Cansiz, S., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b02251 · Cited by 238
Self-citationRelease of Photoactivatable Drugs from Plasmonic Nanoparticles for Targeted Cancer Therapy
Luo, Y.-L., Shiao, Y.-S., & Huang, Y.-F. (2011) · ACS Nano · doi:10.1021/nn201592s · Cited by 233
Circular Bivalent Aptamers Enable in Vivo Stability and Recognition
Kuai, H., Zhao, Z., Mo, L., Liu, H., Hu, X., Fu, T., Zhang, X., & Tan, W. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b04547 · Cited by 222
Potent 2′-amino-, and 2′-fluoro-2′- deoxyribonucleotide RNA inhibitors of keratinocyte growth factor
Pagratis, N. C., Bell, C., Chang, Y.-F., Jennings, S., Fitzwater, T., Jellinek, D., & Dang, C. (1997) · Nature Biotechnology · doi:10.1038/nbt0197-68 · Cited by 221
Liang, C., Li, F., Wang, L., Zhang, Z.-K., Wang, C., He, B., Li, J., Chen, Z., Shaikh, A. B., Liu, J., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.015 · Cited by 216
Self-citationZhu, G., Niu, G., & Chen, X. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00291 · Cited by 213
Modified aptamers enable quantitative sub-10-nm cellular DNA-PAINT imaging
Strauss, S., Nickels, P. C., Strauss, M. T., Jimenez Sabinina, V., Ellenberg, J., Carter, J. D., Gupta, S., Janjic, N., & Jungmann, R. (2018) · Nature Methods · doi:10.1038/s41592-018-0105-0 · Cited by 203
Kong, H. Y., & Byun, J. (2013) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2013.085 · Cited by 202
Aptamer-Based Targeted Drug Delivery Systems: Current Potential and Challenges
He, F., Wen, N., Xiao, D., Yan, J., Xiong, H., Cai, S., Liu, Z., & Liu, Y. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867325666181008142831 · Cited by 201
Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells
Alshaer, W., Hillaireau, H., Vergnaud, J., Ismail, S., & Fattal, E. (2015) · Bioconjugate Chemistry · doi:10.1021/bc5004313 · Cited by 200
Xing, H., Tang, L., Yang, X., Hwang, K., Wang, W., Yin, Q., Wong, N. Y., Dobrucki, L. W., Yasui, N., Katzenellenbogen, J. A., et al. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20412j · Cited by 199
Proximity extension of circular DNA aptamers with real-time protein detection
Di Giusto, D. A. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni063 · Cited by 192
Aptamer-guided nanomedicines for anticancer drug delivery
Alshaer, W., Hillaireau, H., & Fattal, E. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.011 · Cited by 187
Aptamer-Modified Tetrahedral DNA Nanostructure for Tumor-Targeted Drug Delivery
Li, Q., Zhao, D., Shao, X., Lin, S., Xie, X., Liu, M., Ma, W., Shi, S., & Lin, Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b13328 · Cited by 187
Automated Modular Synthesis of Aptamer–Drug Conjugates for Targeted Drug Delivery
Wang, R., Zhu, G., Mei, L., Xie, Y., Ma, H., Ye, M., Qing, F.-L., & Tan, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4117395 · Cited by 181
Liposome-Anchored Vascular Endothelial Growth Factor Aptamers
Willis, M. C., Collins, B., Zhang, T., Green, L. S., Sebesta, D. P., Bell, C., Kellogg, E., Gill, S. C., Magallanez, A., Knauer, S., et al. (1998) · Bioconjugate Chemistry · doi:10.1021/bc980002x · Cited by 181
Spiegelmers: Biostable Aptamers
Eulberg, D., & Klussmann, S. (2003) · ChemBioChem · doi:10.1002/cbic.200300663 · Cited by 181
Burdick, A. D., Sciabola, S., Mantena, S. R., Hollingshead, B. D., Stanton, R., Warneke, J. A., Zeng, M., Martsen, E., Medvedev, A., Makarov, S. S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku142 · Cited by 178
Advancements in Aptamer Discovery Technologies
Gotrik, M. R., Feagin, T. A., Csordas, A. T., Nakamoto, M. A., & Soh, H. T. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00283 · Cited by 177
Multifunctional Aptamer-miRNA Conjugates for Targeted Cancer Therapy
Esposito, C. L., Cerchia, L., Catuogno, S., De Vita, G., Dassie, J. P., Santamaria, G., Swiderski, P., Condorelli, G., Giangrande, P. H., & de Franciscis, V. (2014) · Molecular Therapy · doi:10.1038/mt.2014.5 · Cited by 169
Current Advances in Aptamers for Cancer Diagnosis and Therapy
Hori, S.-I., Herrera, A., Rossi, J., & Zhou, J. (2018) · Cancers · doi:10.3390/cancers10010009 · Cited by 169
Lincoff, A. M., Mehran, R., Povsic, T. J., Zelenkofske, S. L., Huang, Z., Armstrong, P. W., Steg, P. G., Bode, C., Cohen, M. G., Buller, C. E. H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00515-2 · Cited by 167
Bi-specific Aptamers Mediating Tumor Cell Lysis
Boltz, A., Piater, B., Toleikis, L., Guenther, R., Kolmar, H., & Hock, B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.238261 · Cited by 165
Mongélard, F., & Bouvet, P. (2010) · PubMed · Cited by 164
Pharmacokinetics, pharmacodynamics and safety of aptamers
Kovacevic, K. D., Gilbert, J. C., & Jilma, B. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.008 · Cited by 160
Schwoebel, F., van Eijk, L. T., Zboralski, D., Sell, S., Buchner, K., Maasch, C., Purschke, W. G., Humphrey, M., Zöllner, S., Eulberg, D., et al. (2013) · Blood · doi:10.1182/blood-2012-09-456756 · Cited by 158
Wei, X., Tian, T., Jia, S., Zhu, Z., Ma, Y., Sun, J., Lin, Z., & Yang, C. J. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00532 · Cited by 158
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells
Herrmann, A., Priceman, S. J., Kujawski, M., Xin, H., Cherryholmes, G. A., Zhang, W., Zhang, C., Lahtz, C., Kowolik, C. M., Forman, S. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73174 · Cited by 157
de Smidt, P. C., Doan, T. L., Falco, S. D., et al. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.17.4695 · Cited by 155
In Aptamers They Trust: Caveats of the SOMAscan Biomarker Discovery Platform From SomaLogic
Joshi, A., & Mayr, M. (2018) · Circulation · doi:10.1161/circulationaha.118.036823 · Cited by 155
Padilla, R. M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.6.1561 · Cited by 154
Development of aptamer therapeutics
Bunka, D. H. J., Platonova, O., & Stockley, P. G. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.009 · Cited by 153
Derivation of RNA aptamer inhibitors of human complement C5
Biesecker, G., Dihel, L., Enney, K., & Bendele, R. A. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00020-x · Cited by 152
Gupta, S., Hirota, M., Waugh, S. M., Murakami, I., Suzuki, T., Muraguchi, M., Shibamori, M., Ishikawa, Y., Jarvis, T. C., Carter, J. D., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.532580 · Cited by 151
Liposome-Anchored Vascular Endothelial Growth Factor Aptamers
Willis, M. C., Collins, B. T., Zhang, T., Green, L. S., Sebesta, D. P., Bell, C. J., Kellogg, E. A., Gill, S. C., Magallanez, A., Knauer, S., et al. (1998) · Bioconjugate Chemistry · doi:10.1021/bc980200o · Cited by 146
Waters, E. K., Genga, R. M. J., Schwartz, M. C., Nelson, J. A., Schaub, R. G., Olson, K. A., Kurz, J. C., & McGinness, K. E. (2011) · Blood · doi:10.1182/blood-2010-10-311936 · Cited by 143
Matsunaga, K., Kimoto, M., & Hirao, I. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b10767 · Cited by 136
Ninichuk, V., Clauß, S., Kulkarni, O. P., Schmid, H., Segerer, S., Radomska, E., Eulberg, D., Buchner, K., Selve, N., Klußmann, S., et al. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070601 · Cited by 135
Zhuo, Z., Wan, Y., Guan, D., Ni, S., Wang, L., Zhang, Z., Liu, J., Liang, C., Yu, Y., Lü, A., et al. (2020) · Advanced Science · doi:10.1002/advs.201903451 · Cited by 133
Self-citationWu, X., Zhao, Z., Bai, H., Fu, T., Yang, C., Hu, X., Liu, Q., Champanhac, C., Teng, I., Ye, M., et al. (2015) · Theranostics · doi:10.7150/thno.11938 · Cited by 132
Self-citationPrakash, T. P., Yu, J., Migawa, M. T., Kinberger, G. A., Wan, W. B., Østergaard, M. E., Carty, R. L., Vasquez, G., Low, A., Chappell, A. E., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01948 · Cited by 132
Crooke, S. T., Baker, B. F., Xia, S., Yu, R. Z., Viney, N. J., Wang, Y., Tsimikas, S., & Geary, R. S. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0753 · Cited by 127
Evoking picomolar binding in RNA by a single phosphorodithioate linkage
Abeydeera, N., Egli, M., Cox, N., Mercier, K., Conde, J. N., Pallan, P. S., Mizurini, D. M., Sierant, M., Hibti, F.-E., Hassell, T., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw725 · Cited by 122
Shen, W., Hoyos, C. L. D., Sun, H., Vickers, T. A., Liang, X., & Crooke, S. T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky060 · Cited by 115
Calcium-dependent oligonucleotide antagonists specific for L-selectin.
O'Connell, D., Koenig, A. L., Jennings, S. D., Hicke, B. J., Han, H., Fitzwater, T., Chang, Y.-F., Varki, N. M., Parma, D. H., & Varki, A. P. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5883 · Cited by 113
Nanocomposites as biomolecules delivery agents in nanomedicine
Bamburowicz‐Klimkowska, M., Popławska, M., & Grudziński, I. P. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0479-x · Cited by 109
Size-Tunable Assemblies Based on Ferrocene-Containing DNA Polymers for Spatially Uniform Penetration
Tan, J., Li, H., Hu, X., Abdullah, R., Xie, S., Zhang, L., Zhao, M., Luo, Q., Li, Y., Sun, Z., et al. (2019) · Chem · doi:10.1016/j.chempr.2019.05.024 · Cited by 109
Self-citationLee, C. H., Lee, S.-H., Kim, J. H., Noh, Y.-H., Noh, G., & Lee, S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.30 · Cited by 106
Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects
Kruspe, S., & Giangrande, P. H. (2017) · Biomedicines · doi:10.3390/biomedicines5030045 · Cited by 106
Agarwal, S., Simon, A. R., Goel, V., Habtemariam, B. A., Clausen, V. A., Kim, J. B., & Robbie, G. J. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1802 · Cited by 106
Musumeci, D., & Montesarchio, D. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.011 · Cited by 103
Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers
Moreno, A., Pitoc, G. A., Ganson, N. J., Layzer, J. M., Hershfield, M. S., Tarantal, A. F., & Sullenger, B. A. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.001 · Cited by 103
From selection hits to clinical leads: progress in aptamer discovery
Maier, K. E., & Levy, M. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.14 · Cited by 102
Steurer, M., Montillo, M., Scarfò, L., Mauro, F. R., Andel, J., Wildner, S. M., Trentin, L., Janssens, A. M., Burgstaller, S., Frömming, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205930 · Cited by 101
Novel Combinatorial Selection of Phosphorothioate Oligonucleotide Aptamers
King, D. J., Ventura, D. A., Brasier, A. R., & Gorenstein, D. G. (1998) · Biochemistry · doi:10.1021/bi981780f · Cited by 100
Schrand, B., Berezhnoy, A., Brenneman, R., Williams, A. J., Levay, A. K., Kong, L.-Y., Rao, G., Zhou, S., Heimberger, A. B., & Gilboa, E. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0007 · Cited by 98
Jaffe, G. J., Eliott, D., Wells, J. A., Prenner, J. L., Papp, A., & Patel, S. C. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.004 · Cited by 97
LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1
Darfeuille, F. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh636 · Cited by 97
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
Yu, R. Z., Graham, M. J., Post, N. M., Riney, S., Zanardi, T. A., Hall, S., Burkey, J., Shemesh, C. S., Prakash, T. P., Seth, P. P., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.26 · Cited by 97
Hoehlig, K., Maasch, C., Shushakova, N., Buchner, K., Huber-Lang, M. S., Purschke, W. G., Vater, A., & Klußmann, S. (2013) · Molecular Therapy · doi:10.1038/mt.2013.178 · Cited by 93
In Vitro Selection of Circular DNA Aptamers for Biosensing Applications
Liu, M., Yin, Q., Chang, Y., Zhang, Q., Brennan, J. D., & Li, Y. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901192 · Cited by 93
Biodistribution and in vivo toxicity of aptamer-loaded gold nanostars
Dam, D. H. M., Culver, K. S. B., Kandela, I. K., Lee, R. C., Chandra, K., Lee, H., Mantis, C., Ugolkov, A. V., Mazar, A. P., & Odom, T. W. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.10.005 · Cited by 92
Ortigao, J. F. R., Rösch, H., Selter, H., et al. (1992) · Antisense Research and Development · doi:10.1089/ard.1992.2.129 · Cited by 92
Duplex stabilities of phosphorothioate, methylphosphonate, and RNA analogs of two DNA 14-mers
Kibler-Herzog, L., Zon, G., Uznański, B., Whittier, G., & Wilson, W. D. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.11.2979 · Cited by 91
Sinha, A., Gopinathan, P., Chung, Y., Lin, H.-Y., Li, K.-H., Ma, H., Huang, P.-C., Shiesh, S., & Lee, G. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.09.040 · Cited by 91
Bioconjugates for targeted delivery of therapeutic oligonucleotides
Ming, X., & Laing, B. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.002 · Cited by 85
A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells
Esposito, C. L., Nuzzo, S., Kumar, S. A., Rienzo, A., Lawrence, C. L., Pallini, R., Shaw, L., Alder, J. E., Ricci‐Vitiani, L., Catuogno, S., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.032 · Cited by 85
Construction, Stability, and Activity of Multivalent Circular Anticoagulant Aptamers
Giusto, D. A. D., & King, G. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408037200 · Cited by 84
Boyce, M. J., Warrington, S., Cortezi, B., Zöllner, S. K., Vauléon, S., Swinkels, D. W., Summo, L., Schwoebel, F., & Riecke, K. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13433 · Cited by 83
Jacobson, O., Kiesewetter, D. O., & Chen, X. S. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00487 · Cited by 79
Fine, S. L., Martin, D. F., & Kirkpatrick, P. N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1677 · Cited by 79
Floxuridine Homomeric Oligonucleotides “Hitchhike” with Albumin In Situ for Cancer Chemotherapy
Jin, C. Y., Zhang, H., Zou, J., Liu, Y., Zhang, L., Li, F., Wang, R., Xuan, W., Ye, M., & Tan, W. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201804156 · Cited by 78
Self-citationDeng, R., Qu, H., Liang, L., Zhang, J., Zhang, B., Huang, D., Xu, S., Liang, C., & Xu, W. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03971 · Cited by 77
Self-citationUse of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors
Gilboa, E., McNamara, J. O., & Pastor, F. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2067 · Cited by 76
A DNA Spiegelmer to staphylococcal enterotoxin B
Purschke, W. G. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg413 · Cited by 76
Chen, H., Wang, G., Lang, L., Jacobson, O., Kiesewetter, D. O., Liu, Y., Ma, Y., Zhang, X., Wu, H., Zhu, L., et al. (2015) · Theranostics · doi:10.7150/thno.14322 · Cited by 75
Aptamer-based liposomes improve specific drug loading and release
Plourde, K., Derbali, R. M., Desrosiers, A., Dubath, C., Vallée‐Bélisle, A., & Chain, J. L. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.026 · Cited by 71
Soldevilla, M. M., Villanueva, H., Casares, N., Lasarte, J. J., Bendandi, M., Inogés, S., Cerio, A. L.-D. D., & Pastor, F. (2016) · Oncotarget · doi:10.18632/oncotarget.8095 · Cited by 68
Uludağ, H., Ubeda, A., & Ansari, A. S. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00131 · Cited by 67
In vitro selection of phosphorothiolated aptamers
Jhaveri, S. D., Olwin, B. B., & Ellington, A. D. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00414-4 · Cited by 64
Aptamer-targeted Antigen Delivery
Wengerter, B. C., Katakowski, J. A., Rosenberg, J. M., Park, C. G., Almo, S. C., Palliser, D., & Levy, M. (2014) · Molecular Therapy · doi:10.1038/mt.2014.51 · Cited by 64
A Hybrid DNA Aptamer–Dendrimer Nanomaterial for Targeted Cell Labeling
Zhou, J., Soontornworajit, B., Martin, J. T., Sullenger, B. A., Gilboa, E., & Wang, Y. (2009) · Macromolecular Bioscience · doi:10.1002/mabi.200900046 · Cited by 63
Veedu, R. N., & Wengel, J. (2009) · Molecular BioSystems · doi:10.1039/b905513b · Cited by 60
Aptamer-iRNAs as Therapeutics for Cancer Treatment
Soldevilla, M. M., Meraviglia-Crivelli, D., Menon, A. P., & Pastor, F. (2018) · Pharmaceuticals · doi:10.3390/ph11040108 · Cited by 54
Regulation of Protein Activity and Cellular Functions Mediated by Molecularly Evolved Nucleic Acids
Tan, J., Zhao, M., Wang, J., Li, Z., Liang, L., Zhang, L., Yuan, Q., & Tan, W. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201809010 · Cited by 54
Self-citationJeong, H., Hyeon, L. S., Hwang, Y., Yoo, H., Jung, H., Kim, S. H., & Mok, H. (2016) · Macromolecular Bioscience · doi:10.1002/mabi.201600343 · Cited by 52
Physicochemical Stability of NOX-E36, a 40mer L-RNA (Spiegelmer) for Therapeutic Applications
Maasch, C., Buchner, K., Eulberg, D., Vonhoff, S., & Klussmann, S. (2008) · Nucleic Acids Symposium Series · doi:10.1093/nass/nrn031 · Cited by 50
Ma, Y., Zhu, Y., Wang, C., Pan, D., Liu, S., Yang, M., Xiao, Z., Yang, X., Zhao, W., Zhou, X., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.06.012 · Cited by 50
Self-citationImproving Tumor Accumulation of Aptamers by Prolonged Blood Circulation
Ding, D., Cai, Y., Lv, C., Li, J., & Tan, W. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.9b05878 · Cited by 49
Vavalle, J. P., & Cohen, M. G. (2012) · Future Cardiology · doi:10.2217/fca.12.5 · Cited by 48
Stuart, C. H., Singh, R. N., Smith, T. L., D’Agostino, R., Caudell, D. L., Balaji, K., & Gmeiner, W. H. (2016) · Nanomedicine · doi:10.2217/nnm-2015-0017 · Cited by 43
Kinberger, G. A., Prakash, T. P., Yu, J., Vasquez, G., Low, A., Chappell, A. E., Schmidt, K., Murray, H. M., Gaus, H. J., Swayze, E. E., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.05.084 · Cited by 43
Cai, B., Yang, X., Sun, L., Fan, X., Li, L., Jin, H., Wu, Y., Guan, Z., Zhang, L., Zhang, L., et al. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob01525h · Cited by 42
Self-citationBae, O. (2012) · Archives of Pharmacal Research · doi:10.1007/s12272-012-1000-3 · Cited by 41
Keler, T., He, L., Ramakrishna, V., & CHAMPION, B. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210375 · Cited by 40
Jing, P., Cao, S., Xiao, S., Zhang, X., Ke, S., Ke, F., Yu, X., Wang, L., Wang, S., Luo, Y., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.003 · Cited by 37
Self-citationAptamers for CD Antigens: From Cell Profiling to Activity Modulation
Nozari, A., & Berezovski, M. V. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.12.002 · Cited by 37
RNA Aptamers: From Basic Science Towards Therapy
Ulrich, H. (2006) · Springer eBooks · doi:10.1007/3-540-27262-3_15 · Cited by 35
Reiss, D. J., & Mobley, H. L. T. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.290684 · Cited by 32
Li, K., Deng, J., Jin, H., Yang, X., Fan, X., Li, L., Zhao, Y., Guan, Z., Wu, Y., Zhang, L., et al. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob02577c · Cited by 32
Self-citationCosmi, B. (2009) · PubMed · Cited by 31
Barciszewski, J., Medgaard, M., Koch, T., Kurreck, J., & Erdmann, V. A. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-557-2_10 · Cited by 30
Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment
Liu, Y., Wang, G., Zhang, H., Ma, Y., Lang, L., Jacobson, O., Kiesewetter, D. O., Zhu, L., Gao, S., Ma, Q., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00625 · Cited by 30
Liu, B., He, X., Xu, C., Ren, X., Zhuo, R., & Cheng, S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b05772 · Cited by 30
“Albumin Hitchhiking” with an Evans Blue Analog for Cancer Theranostics
Ehlerding, E. B., Lan, X., & Cai, W. (2017) · Theranostics · doi:10.7150/thno.24183 · Cited by 29
Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras
Subramanian, N., Kanwar, J. R., Kanwar, R. K., & Krishnakumar, S. (2015) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0550 · Cited by 28
High-throughput methods in aptamer discovery and analysis
Cole, K. H., & Lupták, A. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.02.009 · Cited by 19
readat: An R package for reading and working with SomaLogic ADAT files
Cotton, R. J., & Graumann, J. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1007-8 · Cited by 18
Tumor-targeted costimulation by using bi-specific aptamers
Pastor, F. (2016) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1333 · Cited by 3
Cited by
Aptamer-functionalized metal-organic frameworks (MOFs) for biosensing
Lv, M., Zhou, W., Tavakoli, H., Bautista, C., Xia, J., Wang, Z., & Li, X. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112947 · Cited by 331
Rouhi, N., Chakeri, Z., Ghorbani Nejad, B., Rahimzadegan, M., Rafi Khezri, M., Kamali, H., & Nosrati, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37533 · Cited by 20
Metadata
- Authors
- Ni, S., Zhuo, Z., Pan, Y., Yu, Y., Li, F., Liu, J., Wang, L., Wu, X., Li, D., Wan, Y., Zhang, L., Yang, Z., Zhang, B.-T., Lu, A., & Zhang, G.
- Venue
- ACS Applied Materials & Interfaces
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-06-30
- Volume
- 13
- Issue
- 8
- Pages
- 9500-9519
- ISSN
- 1944-8244 (ISSN-L)
- 1944-8252
- OpenAlex
- W3038818544
- Cited by
- 589
- References
- 152
- FWCI
- 17.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.